Published in J Clin Oncol on September 22, 2008
Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol (2011) 1.32
Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol (2011) 1.30
Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol (2011) 1.00
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol (2009) 0.96
Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med (2012) 0.90
Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist (2010) 0.88
Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res (2015) 0.87
Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev (2013) 0.86
Metrics to assess quality of life after management of early-stage lung cancer. Cancer J (2011) 0.86
Quality of life during chemotherapy in lung cancer patients: results across different treatment lines. Br J Cancer (2013) 0.83
Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res (2013) 0.83
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Sci Rep (2015) 0.78
Health related quality of life after oesophagectomy: elderly patients refer similar eating and swallowing difficulties than younger patients. BMC Cancer (2015) 0.75
Missing patient-reported outcome data in an adjuvant lung cancer study. J Clin Oncol (2008) 0.75
Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients. Sci Rep (2017) 0.75
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Revisions in the International System for Staging Lung Cancer. Chest (1997) 15.68
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer (2007) 3.06
What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest (2002) 2.79
Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax (2004) 2.77
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res (1996) 2.53
Impact of comorbidity on lung cancer survival. Int J Cancer (2003) 1.95
Adjuvant chemotherapy for lung cancer--a new standard of care. N Engl J Med (2004) 1.88
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer (2005) 1.80
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer (2005) 1.65
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol (2007) 1.57
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer (2006) 1.47
Quality of life following lung cancer resection: video-assisted thoracic surgery vs thoracotomy. Chest (2002) 1.32
Communicating quality of life information to cancer patients: a study of six presentation formats. J Clin Oncol (2005) 1.31
Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol (1996) 1.29
Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol (1997) 1.22
Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 1.19
Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. Clin Cancer Res (2005) 1.17
Quality of life and survival in the 2 years after surgery for non small-cell lung cancer. J Clin Oncol (2007) 1.13
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Quality-of-life following thoracotomy for lung cancer. J Clin Epidemiol (1994) 1.00
Effect of lung cancer surgery on quality of life. Thorax (2005) 0.97
Adjuvant chemotherapy for non-small-cell lung cancer--the smoke clears. N Engl J Med (2005) 0.95
Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol (2006) 0.88
The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual Life Res (1992) 0.85
Outcomes research in lung cancer. J Natl Cancer Inst Monogr (2004) 0.84
Response shift in the perception of health for utility evaluation. an explorative investigation. Eur J Cancer (2001) 0.81
The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer. Clin Cancer Res (2005) 0.80
Adjuvant and neo-adjuvant chemotherapy in non-small cell carcinoma. Ann Oncol (1995) 0.79
Adjuvant treatment of early stage non-small-cell lung cancer. Oncology (Williston Park) (1999) 0.79
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res (2005) 0.79
The importance of chemotherapy dose intensity in lung cancer. Semin Oncol (2004) 0.78
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol (2003) 6.66
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res (2002) 4.92
HER-2 testing in breast cancer using parallel tissue-based methods. JAMA (2004) 4.60
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol (2009) 4.27
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 3.97
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol (2008) 3.83
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res (2002) 3.68
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med (2004) 3.61
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2006) 3.52
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol (2011) 3.51
Non-small-cell lung cancer. Lancet (2011) 3.45
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res (2003) 3.30
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol (2004) 3.02
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A (2009) 2.84
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res (2008) 2.81
Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol (2003) 2.79
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol (2005) 2.76
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol (2008) 2.68
What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol (2002) 2.64
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol (2009) 2.61
A genome-wide association study of red blood cell traits using the electronic medical record. PLoS One (2010) 2.59
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 2.52
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol (2005) 2.36
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol (2007) 2.35
K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer (2006) 2.29
The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2009) 2.29
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem (2004) 2.24
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol (2008) 2.20
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst (2002) 2.19
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol (2005) 2.19
Role of chemotherapy for palliation in the lung cancer patient. J Support Oncol (2007) 2.17
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol (2010) 2.16
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer (2006) 2.14
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol (2006) 2.12
Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol (2007) 2.10